Baseline Hemoglobin and Outcomes in Advanced Chronic Kidney Disease with Moderate-to-Severe Myocardial Ischemia: A Secondary Analysis of the ISCHEMIA-CKD Trial
Journal of Clinical Medicine · 05.11.2026 · 15 (21) · 8610
DOI: 10.3390/jcm15218610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Anar Mammadli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Acıbadem Bayındır Söğütözü Hospital, Ankara 06250, Türkiye. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Hemoglobin may identify differences in prognosis among patients with advanced chronic kidney disease (CKD) and documented myocardial ischemia. We examined the shape of its association with clinical outcomes in ISCHEMIA-CKD.
Methods
This exploratory observational secondary analysis included 758 randomized participants with baseline hemoglobin. The primary endpoint was the parent-trial composite of all-cause death or myocardial infarction (MI). Adjusted Cox regression with restricted cubic splines characterized the hemoglobin association. Mortality and pooled nonfatal MI were examined using Cox and competing-risk models.
Results
Median hemoglobin was 11.1 g/dL; 247 participants experienced the primary endpoint. The adjusted association departed from log-linearity (p = 0.015), with higher hazard at lower hemoglobin and an uncertain upper limb. Relative to 11.1 g/dL, the hazard ratio (HR) at 8 g/dL was 1.98 (95% confidence interval [CI] 1.26–3.10). As a linear summary, the HR per 1 g/dL lower hemoglobin was 1.13 (95% CI 1.04–1.23) for the primary endpoint. Corresponding mortality associations were present, whereas pooled nonfatal MI showed no clear association (subdistribution HR 1.03, 95% CI 0.89–1.21). Exploratory treatment interaction tests provided no convincing evidence of effect modification (linear p = 0.059; spline p = 0.124).
Conclusions
Among selected, clinically stable participants with advanced CKD and moderate-to-severe ischemia, lower baseline hemoglobin was associated with adverse prognosis. Nonlinearity and uncertainty at higher values argue against a single summary estimate or an inferred optimal target. These potentially confounded findings neither establish benefit from hemoglobin correction nor support hemoglobin-based selection of invasive versus conservative management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Acıbadem Bayındır Söğütözü Hospital, Ankara 06250, Türkiye.
- Department of Cardiology, School of Medicine, Ankara Medipol University, Ankara 06050, Türkiye.
Zitieren
APA
Mammadli, A., & Diker, E. (2026). Baseline Hemoglobin and Outcomes in Advanced Chronic Kidney Disease with Moderate-to-Severe Myocardial Ischemia: A Secondary Analysis of the ISCHEMIA-CKD Trial. Journal of Clinical Medicine, 15(21), 8610. https://doi.org/10.3390/jcm15218610
Vancouver
Mammadli A, Diker E. Baseline Hemoglobin and Outcomes in Advanced Chronic Kidney Disease with Moderate-to-Severe Myocardial Ischemia: A Secondary Analysis of the ISCHEMIA-CKD Trial. Journal of Clinical Medicine. 2026;15(21):8610. doi:10.3390/jcm15218610
BibTeX
@article{Mammadli2026,
author = {Mammadli, Anar and Diker, Erdem},
title = {Baseline Hemoglobin and Outcomes in Advanced Chronic Kidney Disease with Moderate-to-Severe Myocardial Ischemia: A Secondary Analysis of the ISCHEMIA-CKD Trial},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8610},
doi = {10.3390/jcm15218610}
}
EUVIMED